24th Annual Scientific and Clinical Congress

Register Here

Congress Program Agenda with Educational Objectives

WEDNESDAY, MAY 13

6:30 am - 6:30 pm Attendee Registration
12:30 pm - 6:30 pm CME Station Hours
8:00 am - 12:00 pm SPECIAL SESSION I
 

W11: Hot Topics in Thyroid Practice

Chair: Hossein Gharib, MD

Room: 101 DE
CME Code: 6135

 

W21: Diabetes Technology Update for Your Practice
Chair: George Grunberger, MD

Room: 102 AB
CME Code: 5096
 

W31: DXA for the Practicing Endocrinologist: What Every Clinician Needs to Know
Chair: Susan E. Williams, MD

Room: 101 B
CME Code: 7124
 

W41: Leadership Forum
Co-Chairs: Howard M. Lando, MD & Anne L. Leddy, MD
Speakers: Tara Hickey & Eric Martin

  • What Leadership Role Can We Play as Champions for Clinical Endocrinologists?
  • What is the Nature of Leadership Work Required for Example to Strengthen Membership and improve the Chapter Effectiveness?
  • What Personal Adaptations May be Required so That We Can More Effectively Lead Consequential Change?

Room: 101 A
CME Code: 1606

1:00 pm - 5:00 pm SPECIAL SESSION II
 

W12: The AACE Module and Tool Kit for Obesity Medicine
Chair: W. Timothy Garvey, MD

Room: 101 B
CME Code: 3467
 

W22: Challenging Topics in Pituitary and Adrenal Disorders
Co-Chairs: Richard J. Auchus, MD & Laurence Katznelson, MD

Room: 101 DE
CME Code: 8382
 

W32: 2015 Diabetes Update
Co-Chairs: Vivian A. Fonseca, MD & Etie S. Moghissi, MD

Room: 102 AB
CME Code: 2035
 

W42: Endocrinology in the Real World
Co-Chairs: Bill Law, Jr., MD & Katherine A. Roberts, MD

Room: 101 A
CME Code: 1122
1:00 pm - 5:30 pm

W52: AACE Maintenance of Certification and Mini-Board Review Course
Chair: Pauline M. Camacho, MD
Speakers: Elise M. Brett, MD, Pauline M. Camacho, MD, & Hossein Gharib, MD

  • To discuss recent updates on the endocrine certification process
  • To discuss ASAP 2014 Thyroid Module
  • To discuss ASAP 2014 Parathyroid & Bone Module

Room: 101 C
CME Code: 7892

5:30 pm - 7:45 pm

WSS1: LDL-C Reduction in the High-Risk Patient: How Low Should We Go?
Room: Omni Nashville - Legends Ballroom ABC
CME Code: 2454

THURSDAY, MAY 14

5:15 am - 7:30 am

TSS1: Overcoming Barriers in Diabetes Management with Individualized Treatment Strategies
Room: Omni Nashville - Legends Ballroom ABC
CME Code: 5456

6:30 am - 6:00 pm Attendee Registration
7:00 am - 6:00 pm CME Station Hours
9:45 am - 2:15 pm Exhibit Hall Hours
8:00 am - 8:15 am General Session Announcements
8:15 am - 9:00 am

TGS1: Bionic Pancreas
Moderator: R. Mack Harrell, MD
Speaker: Edward R. Damiano, MD
Room: BALLROOM A
CME Code: 1348

9:00 am - 9:45 am

TGS2: Neonatal Diabetes: Identification, Initial Treatment, and Transitioning the Parent
Moderator: Yehuda Handelsman, MD
Speaker: Siri A.W. Greeley, MD

Room: BALLROOM A

CME Code: 2924
9:45 am - 11:00 am Exhibit Hall Coffee Break
10:00 am - 10:45 am Product Theaters in the Exhibit Hall
11:00 am - 11:45 am

TGS3: Microarchitectural of Bone and its Clinical Relevance
Moderator: Pauline M. Camacho, MD
Speaker: John Paul Bilezikian, MD
Room: BALLROOM A
CME Code: 6520

11:45 am - 12:30 pm

TGS4: The Link Between Retinopathy and VEGF: The Journey from Discovery through Clinical Therapy
Moderator: Sandra L. Weber, MD
Speaker: Michael J. Tolentino, MD
Room: BALLROOM A
CME Code: 1764

12:30 pm - 2:15 pm President’s Welcome Box Lunch in Exhibit Hall
12:45 pm - 1:30 pm

Product Theaters in the Exhibit Hall

12:30 pm - 2:15 pm

Women of Endocrinology Luncheon: If I Knew Then, What I Know Now (non-CME)
Moderator: Etie S. Moghissi, MD
Speaker: Camille Lee, Senior Vice President, Diabetes Marketing for Novo Nordisk Inc.

2:15 pm - 3:15 pm Meet-the-Experts
 

SESSION I

 

T11: Of Hispanics and Metabolism: Understanding the Risk for Diabetes
Moderator: Donald A. Bergman, MD
Speaker: Jaime A. Davidson, MD
Room: 101 B
CME Code: 2502

 

T21: Testosterone Use: When and How; Testosterone Treatment in Young Males
Moderator: Elise M. Brett, MD
Speaker: Paul Turek, MD
Room: 104 ABC
CME Code: 4276

 

T31: Practicalities in the Use of Pharmacologic Agents
Moderator: Felice A. Caldarella, MD
Speaker: Caroline Apovian, MD
Room: 101 A
CME Code: 4366

 

T41: Thyroid Ultrasound Images
Moderator: Mark A. Lupo, MD
Speaker: Robert A. Levine, MD
Room: 103 ABC
CME Code: 3031

 

T51: Controversies in Osteoporosis Management
Moderator: Daniel L. Hurley, MD
Speaker: Felicia Cosman, MD
Room: 101 CDE
CME Code: 2749

 

T61: (Point/Counterpoint) Subclinical Hypothyroidism: Treat or Not
Moderator: Peter A. Singer, MD
Speaker Point: Paul W. Ladenson, MD
Speaker Counter: Jeffrey R. Garber, MD
Room: 104 DE
CME Code: 2533

 

T71: (Case Review) Challenging Lipid Cases
Moderator: David S. H. Bell, MD
Speaker: Lisa Tannock, MD
Room: 102 AB
CME Code: 3370

3:15 pm - 3:30 pm Coffee Break
3:30 pm - 4:30 pm

Meet-the-Expert

 

SESSION II

 

T12: Emerging Therapies and Technologies for the Treatment of Diabetes
Moderator: S. Sethu K. Reddy, MD
Speaker: Irl B. Hirsch, MD
Room: 104 ABC
CME Code: 9140

 

T22: Update on PCKS9 Inhibitors and New Therapies
Moderator: M. Kathleen Figaro, MD
Speaker: Evan A. Stein, MD
Room: 101 CDE
CME Code: 3961

 

T32: Challenges in Management of the Endocrine Patient: Transition of Care from Pediatric to Adult Endocrinology
Moderator: Rajib Bhattacharya, MD
Speaker: A. Jay Cohen, MD
Room: 101 A
CME Code: 8484

 

T42: The Nutritional Prevention and Reversal of Cardiovascular Disease-Fact or Fiction?
Moderator: Chris K. Guerin, MD
Speaker: Caldwell B. Esselstyn, Jr., MD
Room: 102 AB
CME Code: 5611

 

T52: The Mind’s Role in Obesity
Moderator: Michael A. Bush, MD
Speaker: Joshua P. Thaler, MD
Room: 104 DE
CME Code: 3053

 

T62: Ectopic ACTH: Diagnosis and Treatments
Moderator: Janet B. McGill, MD
Speaker: Maria Fleseriu, MD
Room: 101 B
CME Code: 2300

 

T72: (Case Review) Update on Pheochromocytoma and Paraganglioma: Implications for Clinical Practice
Moderator: Rachel Pessah-Pollack, MD
Speaker: Karel Pacak, MD
Room: 103 ABC
CME Code: 8408

4:45 pm - 5:45 pm

Meet-the-Experts
SESSION III

 

T13: Diabetes Transition from Pediatrics to Adulthood
Moderator: Dace L. Trence, MD
Speaker: Jennifer Raymond, MD
Room: 102 AB
CME Code: 6174

 

T23: Statin Intolerance: Statin Side-Effects?
Moderator: Richard A. Haas, MD
Speaker: Lisa Tannock, MD
Room: 101 CDE
CME Code: 4043

 

T33: Late-Effects in the Emerging Population of Childhood Cancer Survivors
Moderator: Vin Tangpricha, MD
Speaker: Sripriya Raman, MD
Room: 101 A
CME Code: 9536

 

T43: Ectopic ACTH: Diagnosis and Treatments
Moderator: Janet B. McGill, MD
Speaker: Maria Fleseriu, MD
Room: 101 B
CME Code: 1816

 

T53: Thyroid Ultrasound Images
Moderator: Mark A. Lupo, MD
Speaker: Robert A. Levine, MD
Room: 103 ABC
CME Code: 1868

 

T63: The Mind’s Role in Obesity
Moderator: Michael A. Bush, MD
Speaker: Joshua P. Thaler, MD
Room: 104 DE
CME Code: 1352

 

T73: (Case Review) Challenging Thyroid Cases
Moderator: Robert S. Zimmerman, MD
Speakers: Paul W. Ladenson, MD & Susan J. Mandel, MD
Room: 104 ABC
CME Code: 5848

6:00 pm - 7:00 pm

Chapter & International Receptions

7:30 pm - 9:45 pm

TSS3: Paradigm Shifts in Hypoparathyroidism: How New Insights in Epidemiology and Treatment are Changing the Standard of Care
Room: Omni Nashville - Legends Ballroom ABC
CME Code: 8313

7:30 pm - 9:45 pm

TSS4: Combination Therapy in Type 2 Diabetes Management: Charting Courses for Success
Room: Omni Nashville - Legends Ballroom EFG
CME Code: 4711

FRIDAY, MAY 15

5:15 am - 7:30 am

FSS1: Prevention and Management of Diabetic Retinopathy and Related Eye Disorders: Clarifying the Endocrinologist's Role
Room: Omni Nashville - Legends Ballroom ABC
CME Code: 4117

5:15 am - 7:30 am

FSS2: Applying the Fundamentals of Insulin Physiology to Modernize Exogenous Insulin Therapy: An Expert Panel Exchange and Interactive Town Hall Discussion
Room: Omni Nashville - Legends Ballroom EFG
CME Code: 3879

7:30 am - 5:30 pm

Attendee Registration

7:30 am - 6: 30 pm CME Station Hours
9:45 am - 2:15 pm Exhibit Hall Hours
8:00 am - 8:15 am General Session Announcements
8:15 am - 9:00 am

FGS1: Molecular Drivers for Fat Genesis and their Roles in Diabetes and Obesity
Moderator: Daniel Einhorn, MD
Speaker: Ronald Evans, PhD
Room: BALLROOM A
CME Code: 9031

9:00 am - 9:45 am

FGS2: Short-Term and Long-Term Impacts of Genetic Discovery on the Practice of Endocrinology
Moderator: Robert Rapaport, MD
Speaker: Joel Hirschhorn, MD
Room: BALLROOM A
CME Code: 6570

9:45 am - 11:00 am Exhibit Hall Coffee Break
10:00 am - 10:45 am Product Theaters in Exhibit Hall
11:00 am - 12:30 pm Mini Plenary Sessions
 

FGS3: Transcultural Endocrinology Symposium
Chair/Moderator: Jeffrey I. Mechanick, MD

Room: 101 CDE
CME Code: 6411
11:00 am - 11:45 am

FGS4: Oral Poster Presentations
Moderators: Edward S. Horton, MD & David S. Lieb, MD
Room: 103 ABC
CME Code: 1482

 

FGS5: Thyroid: The Year in Review
Moderator: Peter A. Singer, MD
Speaker: Susan J. Mandel, MD
Room: 104 ABC
CME Code: 2044

11:45 am - 12: 30 pm

FGS6: Late Breaking Clinical Trials (non-CME)
Moderators: Alan J. Garber, MD, Janet B. McGill, MD, & Vin Tangpricha, MD
Room: 104 ABC

 

FGS7: Oral Poster Presentations
Moderators: Edward S. Horton, MD & David C. Lieb, MD
Room: 103 ABC
CME Code: 9498

12:30 pm - 2:15 pm Exhibit Hall Break
12:45 pm - 1:30 pm Product Theaters in Exhibit Hall
2:15 pm - 5:00pm In-Depth Symposia
 

F11: Transition from Childhood to Adulthood
Chair: Robert Rapaport, MD

Room: 101 A
CME Code: 9762
 

F21: Advances in Thyroid Cancer
Chair: Hossein Gharib, MD

Room: 104 ABC
CME Code: 7689
 

F31: Updates on Osteoporosis and Metabolic Bone Disease
Chair: Pauline M. Camacho, MD

Room: 101 CDE
CME Code: 5982
 

F41: Assessing the Benefits and Risks of Testosterone Therapy in Men and Women
Co-Chairs: Paresh Dandona, MD & Neil F. Goodman, MD

Room: 104 DE
CME Code: 7112

 

F51: Novel Therapeutic Approaches to Type 2 Diabetes and Complications
Chair: Robert R. Henry, MD

Room: 103 ABC
CME Code: 9927

 

F61: Lipid Guidelines: Can We Identify the Risk, but Not the Numbers?
Chair: Kathleen L. Wyne, MD

Room: 102 AB
CME Code: 4819

 

F71: AACE/SMNE Pan American Symposia: Lifestyle, Metabolic Disorders and Cancer
Co-Chairs: Myriam Allende-Vigo, MD

Room: 101 B
CME Code: 6499

5:00 pm - 6:30 pm Exhibit Hall Wine & Cheese Reception
7:00 pm - 9:15 pm

FSS3: Continuous Coverage and Clinical Application of Real-Time CGM: Pathway to Improved Outcomes and Reduced Cost
Room: Omni Nashville - Legends Ballroom ABC
CME Code: 7276

7:00 pm - 9:15 pm

FSS4: Managing Obesity in 2015: Setting the Framework and Assessing All of the Options
Room: Omni Nashville - Legends Ballroom EFG
CME Code: 6985

SATURDAY, MAY 16

7:30 am - 5:00 pm Attendee Registration
7:30 am - 6:00 pm CME Station Hours
9:45 am - 1:00 pm Exhibit Hall Hours
8:00 am - 8:15 am General Session Announcements
8:15 am - 9:00 am

SGS1: The Three Pathways of Translational Research: Diabetes and a Personal Experience
Moderator: Jeffrey I. Mechanick, MD
Speaker: Valentin Fuster, MD
Room: BALLROOM A
CME Code: 6637

9:00 am - 9:45 am

SGS2: Deletions and Mutations in Growth Hormone- Receptor (Laron Syndrome): Genetic, Biological, and Clinical Aspects
Moderator: Jaime A. Davidson, MD
Speaker: Zvi Laron, MD
Room: BALLROOM A
CME Code: 9226

9:45 am - 11:00 am Exhibit Hall Coffee Break
10:00 am - 10:45 am Product Theaters in Exhibit Hall
11:00 am - 11:45 am

SGS3: Metformin: Its Non-Glycemic Effects and Cardiovascular Risk Reduction
Moderator: Anne L. Leddy, MD
Speaker: John M. Miles, MD
Room: BALLROOM A
CME Code: 5263

11:45 am - 12:30 pm

SGS4: Disordered Growth Hormone Secretion in HIV: Mechanisms and Novel Therapeutic Strategies
Moderator: Felice A. Caldarella, MD
Speaker: Steven K. Grinspoon, MD
Room: BALLROOM A
CME Code: 6442

12:30 pm - 2:15 pm AACE Annual Business Meeting Luncheon
2:15 pm - 3:15 pm

Meet-the-Expert
SESSION I

 

S11: Year in Diabetes
Moderator: Etie S. Moghissi, MD
Speaker: Claresa S. Levetan, MD
Room: 104 ABC
CME Code: 3747

 

S21: FGF: New Guy on the Scene
Moderator: Sunil Wimalawansa, MD
Speaker: Bryan Kestenbaum, MD
Room: 101 A
CME Code: 4062

 

S31: Neurohumoral Syndromes
Moderator: Derek LeRoith, MD
Speaker: Aaron I. Vinik, MD
Room: 101 B
CME Code: 1351

 

S41: Hyperandrogenic Anovulation
Moderator: W. Reid Litchfield, MD
Speaker: Margaret E. Wierman, MD
Room: 103 ABC
CME Code: 8295

 

S51: The Year in Pituitary Disease
Moderator: Ved V. Gossain, MD
Speaker: Mark E. Molitch, MD
Room: 101 CDE
CME Code: 5747

 

S61: (Point/Counterpoint) To Use or Not Molecular Markers
Moderator: Jonathan D. Leffert, MD
Speaker Point: Bryan McIver, MD
Speaker Counter: Mark A. Lupo, MD
Room: 102 AB
CME Code: 4172

 

S71: (Case Review) Thyroid Cases: Weird and the Not So Unusual
Moderator: Farhad Zangeneh, MD
Speaker: Jeffrey R. Garber, MD
Room: 104 DE
CME Code: 4888

3:15 pm - 3:30 pm Coffee Break
3:30 pm - 4:30 pm

Meet-the-Experts
SESSION II

 

S12: Update on the Impact of Sleep Disturbances in Metabolic Disorders
Moderator: Joseph Aloi, MD
Speaker: Eve Van Cauter, MD
Room: 101 CDE
CME Code: 2049

 

S22: ICD-10
Moderator: Katherine A. Roberts, MD
Speaker: Todd W. Frieze, MD
Room: 104 DE
CME Code: 7338

 

S32: Lipidystrophy
Moderator: Felice A. Caldarella, MD
Speaker: Savitha Subramanian, MD
Room: 102 AB
CME Code: 9000

 

S42: PCOS in Adolescent Girls: Diagnosis and Management
Moderator: Sripriya Raman, MD
Speaker: Selma F. Witchel, MD
Room: 104 ABC
CME Code: 7621

 

S52: Treatment of Progressive Thyroid Cancer
Moderator: Gregory Randolph, MD
Speaker: Steven I. Sherman, MD
Room: 103 ABC
CME Code: 5732

 

S62: Neurohumoral Syndromes
Moderator: Derek LeRoith, MD
Speaker: Aaron I. Vinik, MD
Room: 101 B
CME Code: 2930

 

S72: Preventing Type 2 Diabetes in Latino Youth: translational Science to Clinical Relevance
Moderator: Craig Wierum, MD
Speaker: Gabriel Q. Shaibi, MD
Room: 101 A
CME Code: 5415

4:45 pm- 5:45 pm SESSION III
  Meet-the-Experts
 

S13: Normocalcemic Hyperparathyroidism
Moderator: Gary W. Edelson, MD
Speaker: Shonni J. Silverberg, MD
Room: 104 ABC
CME Code: 3027

 

S23: Endocrine Jeopardy
Moderator: Ricardo Correa, MD
Speaker: Cheryl Rosenfeld, MD
Room: 104 DE
CME Code: 9598

 

S33: Update on the Impact of Sleep Disturbances in Metabolic Disorders
Moderator: Joseph Aloi, MD
Speaker: Eve Van Cauter, MD
Room: 101 CDE
CME Code: 2554

 

S43: Subclinical Cushing’s
Moderator: Donald W. Richardson, MD
Speaker: John D. Carmichael, MD
Room: 102 AB
CME Code: 5477

 

S53: Neutroceuticals
Moderator: Shashank R. Joshi, MD
Speaker: Kenneth D. Burman, MD
Room: 101 A
CME Code: 7915

 

S63: Treatment of Progressive Thyroid Cancer
Moderator: Gregory Randolph, MD
Speaker: Steven I. Sherman, MD
Room: 103 ABC
CME Code: 9199

 

S73: (Point/Counterpoint) Data on Ethnic Disparities in Diabetes Prevalence
Moderator: Gary A. Trager, MD
Speaker Point: Elizabeth Selvin, MD
Speaker Counter: Samuel Dagogo-Jack, MD
Room: 101 B
CME Code: 7635

6:30 pm ACE Convocation
7:30 pm President’s Gala

SUNDAY, MAY 17

7:00 am - 11:30 am Attendee Registration
7:30 am - 12:00 pm CME Station Hours
7:00 am - 8:00 am

Breakfast
Room: BALLROOM A

8:00 am - 8:15 am

General Session Announcements

8:00 am - 11:00 am

Oral Presentations on Planning Research in Diabetes (PRIDE) F(non-CME)

Room: 108
8:15 am - 9:00 am

SGS5: AACE/AAES Joint Review of Cases on Hyperparathyroidism

Moderator: Nancy D. Perrier, MD Speakers: Mira Milas, MD & Shonni J. Silverberg, MD
Room: BALLROOM A
CME Code: 5183

9:15 am - 10:00 am

SGS6: AACE/AAES Joint Review of Cases on Thyroid Cancer Management

Moderator: Carmen C. Solorzano, MD
Speakers: Gregory Randolph, MD & R. Michael Tuttle, MD
Room: BALLROOM A
CME Code: 9932

10:15 am - 11:00 am

SGS7: AACE/AAES Joint Review of Cases on Adrenal Nodules

Moderator: Gerard Doherty, MD
Speakers: Clive S. Grant, MD & Gary D. Hammer, MD
Room: BALLROOM A
CME Code: 5590

11:00 am - 11:15 am Final Announcements; Adjournment
WEDNESDAY, MAY 13
8:00 am - 12:00 pm SPECIAL SESSION I
  W11: Hot Topics in Thyroid Practice
Chair: Hossein Gharib, MD
  • Molecular Markers in 2015
    Yuri Nikiforov, MD
  • Highlights of Thyroid Cancer Guidelines
    Bryan R. Haugen, MD
  • T3 Plus T4 Combination Therapy: Yes or No?
    Antonio Binaco, MD
  • Minimally-Invasive Rx in Thyroid Practice
    Laszlo Hegedus, MD
EDUCATIONAL OBJECTIVES:
  • To provide an overview of molecular alterations in thyroid tumors.
  • To discuss diagnostic utility of molecular markers for thyroid nodules and cancer.
  • To discuss prognostic utility of molecular markers for risk stratification of thyroid cancer.
EDUCATIONAL OBJECTIVES:
  • Understand basic changes in the 2015 guidelines compared with the 2009 guidelines
  • Apply new recommendations on management of patients with thyroid nodules and differentiated thyroid cancer to clinical practice
  • Understand the strengths and limitations of these guidelines and individual recommendations
EDUCATIONAL OBJECTIVES:
  • Understand sources and maintenance mechanism of plasma T3
  • Understand the deiodinase pathways involving T3 productions
  • Understand mechanism of regulating TSH secretions
EDUCATIONAL OBJECTIVES:
  • Identify patients eligible for and benefitting from non-surgical therapy for benign thyroid nodules
  • Describe the major technologies for minimally invasive therapy for benign thyroid nodules
  • Recommendations in relation to benign thyroid nodules phenotypes.
  W21: Diabeters Technology Update for Your Practice
Chair: George Grunberger, MD
  • Current Pump and CGM
    Bruce W. Bode, MD
  • Case Studies: Interpreting Pump and CGM Downloads
    Irl B. Hirsch, MD
  • The Future: Artificial Pancreas and Closed Loop Control
    Timothy S. Bailey, MD
EDUCATIONAL OBJECTIVES:
  • Be aware of the current pumps and CGM devices on the market
  • Be able to list the Indications for CGM devices
  • Be able to list the indications for Insulin Pumps
EDUCATIONAL OBJECTIVES:
  • Review both basic and advanced understanding of statistical interpretation of blood glucose data
  • Interpret pump download with special emphasis on appreciation of use of bolus calculator over-rides
  • Interpret simple and unusual downloads of both major CGM devices used in the US in 2014
EDUCATIONAL OBJECTIVES:
  • Identify patients that might benefit clinically from low glucose suspend insulin pumps
  • Understand the FDA's regulatory pathway to the "artificial pancreas" and why getting new technology to patients is difficult
  • Recognize the technological challenges with the artificial pancreas: glucose sensing, insulin delivery, and automated insulin dose calculations
  W31: DXA for the Practicing Endocrinologist: What Every Clinicain Needs to Know
Chair: Susan E. Williams, MD
  • DXA to Diagnosis: the Challenges of DXA in Medical Practice
    Angelo A. Licata, MD
  • New Osteoporosis Guidelines
    Pauline M. Camacho, MD & Steven M. Petak, MD
  • Update in Bone Densitometry: New and Emerging Technologies
    Susan Broy, MD
  • Challenging Cases: Making the Diagnosis, assessing Treatment Efficacy, and “
    What in the World?”
    Susan E. Williams, MD
EDUCATIONAL OBJECTIVES:
  • Recognize the methodology of DXA scanning
  • Identify the reasons for potential problems in reports
  • Develop awareness about reporting errors and ways to correct for them
EDUCATIONAL OBJECTIVES:
  • Learn the utility and application of bone densitometry to management of post-menopausal osteoporosis patients based on guidelines
  • Understand the approach to evaluation of the patient with post-menopausal osteoporosis based on guidelines
  • Learn the therapy approach to prevention and treatment of post-menopausal osteoporosis.
EDUCATIONAL OBJECTIVES:
  • List ISCD official positions on the use of TBS and QCT in assessing fracture risk
  • Explain the role of hip geometry in bone strength
  • Describe the role of microarchitecture in bone strength
EDUCATIONAL OBJECTIVES:
  • Identify 3 common sources of error when interpreting bone density tests
  • Recognize the importance of looking at the DXA images
  • Understand the utility and the limitations of using DXA for diagnosis and assessing Treatment efficacy
  W41: Leadership Forum
Chairs: Howard M. Lando, MD;& Anne L. Leddy, MD
Speakers: Eric Martin, & Tara Hickey
  • What Leadership Role can we play as Champions for Clinical Endocrinology?
  • What is the Nsture of Leadership Work required for example to strengthen membersjip and improve the chapter effectiveness?
  • What personal adapttaions may be required so that we can more effectively lead consequential change?
EDUCATIONAL OBJECTIVES:
  • Attendees will be able to describe different practice models available to Endocrinologists.
  • To help prepare you for your future in medicine, whatever it may hold
  • Attendees will be able to understand principles of effective leadership regardless of practice or organization.
  • To identify skills that will help you succeed in whatever path your career may follow.
  • Attendees will learn about effective communication.
  • To help you enhance your ability to communicate with supervisors, employees, colleagues, patients and others in your career.
  • Attendees will hear from effective leaders in different practice models.
  • To help you prepare for the future of your career as it evolves in the future.
1:00 pm - 5:00 pm SPECIAL SESSION II
  W12: The AACE Module and Tool Kit for Obesity
Chair: W. Timothy Garvey, MD
  • Guidelines and The Practice of Obesity Medicine
    W. Timothy Garvey, MD
  • Step 1: The Anthropometric Component of the Diagnosis
    J. Michael Gonzalez-Campoy, MD
  • Step 2: the Clinical Component of the Diagnosis
    Felice A. Caldarella, MD
  • The Complications Centric Approach
    W. Timothy Garvey
  • Step 3: The Therapeutic Decision
    Donna Ryan, MD
  • Logstics, Finances and Coding for a Successful Obesity Medicine Practice
    Felice A. Caldraella, MD & J. Micheal Gonzalez-Campoy
EDUCATIONAL OBJECTIVES:
  • To review the infrastructure needed for effective obesity care
  • To define a structured approached to chronic obesity care
  • To discuss effective ways to secure a healthy revenue stream for a bariatric endocrinology practice
EDUCATIONAL OBJECTIVES:
  • Describe the essentials of the obesity-focused history
  • Review the essentials of the physical examination of the obesity patient
  • Describe the laboratory evaluation of the obese patient
  W22: Challenging Topics in Pituitary and Adrenal Disorders
Co-Chairs: Richard J. Auchus MD;& laurence Katznelson, MD
  • Approach to Sellar Mass: Radiologic Images and Brief Discussion
    Laurence Katznelson, MD
  • Medical Mangement of Cushing’s Disesae
    Susan L. Samson, MD
  • Genetics of Adrenal Disesae
    Richard J. Auchus, MD
  • Approach to a Patient with a Possible Pheochromocytoma
    Karel Pacak, MD
EDUCATIONAL OBJECTIVES:
  • Identify the causes of a pituitary incidentaloma.
  • Describe the diagnostic approach to a patient with a sellar mass.
  • Identify therapeutic approaches to a sellar mass.
EDUCATIONAL OBJECTIVES:
  • Describe the mechanism of action of available medical therapies for Cushing's disease
  • Discuss efficacy and outcomes of medical therapies for Cushing's disease
  • Describe the most common adverse effects of medical therapies for Cushing's disease
EDUCATIONAL OBJECTIVES:
  • Compare and contrast the patterns of steroid excess and deficiency in the different forms of congenital adrenal hyperplasia.
  • Describe how mutations in ion channels and ion pumps cause primary aldosteronism.
  • List several genetic defects causing primary adrenal insufficiency.
EDUCATIONAL OBJECTIVES:
  • Learn about clinical presentations of pheochromocytoma and pseudopheochromocytoma
  • Learn about newest biochemical approaches to prove or rule out Pheochromocytoma
  • Learn about recommended imaging approaches to localize Pheochromocytoma
  W32: 2015 Diabetes Update
Co-Chairs: Vivian A. Fonseca, MD; & Etie S. Moghissi, MD
  • New Understanding of the Pathophysiology of Type 2 Diabetes: The Role of Glucagon
    Ralph A. DeFronzo, MD
  • Cardiovascular Safety of Incretin Based Therapy
    John B. Buse, MD
  • New Approaches to Insulin Therapy in Combination
    Vivian A. Fonseca, MD
  • What an Endocrinologists Should Know About Eye Care and Retinopathy
    Michael J. Tolentino, MD
EDUCATIONAL OBJECTIVES:
  • To understand the multiple physiologic abnormalities responsible for impaired glucose homeostasis in T2DM
  • To understand the role of glucagon in the pathophysiology of T2DM
  • To appreciate what therapeutic interventions can reduce plasma glucagon levels and HGP in T2DM
EDUCATIONAL OBJECTIVES:
  • Understand preclinical data on Incretin effects in the cardiovascular system
  • Recognize the CHF signal from the DPP-4 inhibitor trials published to date
  • Recognize the meta-analyzed data from RCT's on CVD safety from Incretin therapies and the upcoming CVOT's
EDUCATIONAL OBJECTIVES:
  • Understand when basal insulin fails
  • Discuss adding Prandial insulin
  • Discuss adding other agents (non-insulin) to basal insulin
EDUCATIONAL OBJECTIVES:
  • Identify patients that require referral to an ophthalmologist.
  • Understand the algorithm that is used to treat patients with diabetic retinopathy
  • Comprehend the scope of diabetic retinopathy and the novel treatments being developed for the condition
  W42: Endocrinology in the Real World
Co-Chairs:Bill Law, Jr., MD & Katherine A. Roberts, MD
  • Social Media and Medicine
    Thomas B. Repas, MD
  • The Psychology of Negotiations and Advocacy
    Dan O’Connell, MD
  • Optimal Incorporation of Extenders into an Endocrine Practice
    Bill Law, Jr., MD
  • What are RVUs and How do We get Piad on Them?
    M Kathleen Figaro, MD
EDUCATIONAL OBJECTIVES:
  • Recognize the various types of social media and differentiate between social media and other forms of health care technology
  • Identify how social media can be beneficial in communicating, collaborating and engaging with our patients and other health care
  • professionals
Indicate some of the potential risks and challenges of social media in medicine

EDUCATIONAL OBJECTIVES:
  • See how, when and where negotiating is the best approach to reaching mutually agreed upon plans
  • Describe the 5 Step Approach to Negotiating
  • Apply the steps to a few common clinical situations
EDUCATIONAL OBJECTIVES:
  • TBD
EDUCATIONAL OBJECTIVES:
  • Identify different payment structures in clinical practice.
  • Discuss the benefits of RVUs.
  • Discuss the possible harms of payment using RVUs.
1:00 pm - 5:30 pm W52: AACE Maintenance of Certification & Mini-Board Review Course
Chair: Pauline M. Camacho, MD
Speakers
  • Elise M. Brett, MD
  • Pauline M. Camacho, MD
  • Hossein Gharib, MD
EDUCATIONAL OBJECTIVES:
  • To discuss recent updates on the endocrine certification process
  • To discuss ASAP 2014 Thyroid Module
  • To discuss ASAP 2014 Parathyroid & Bone module
5:30 pm – 7:45 pm WSS1: LDL-C Reduction in High Risk Patient: How Low Should We Go?
5:30 pm – 6:00 pm Dinner
THURSDAY, MAY 14
5:15 am - 7:30 am TSS1: Overcoming Barriers in Diabetes Management with Individualized Treatment Strategies
5:15 am - 5:45 am Breakfast
6:30 am - 6:00 pm Attendee Registration
7:00 am - 6:00 pm CME Station Hours
9:45 am - 2:15 pm Exhibit Hall Hours
8:00 am - 8:15 am General Session Announcements
8:15 am - 9:00 am

TGS1: Outpatient Studies of the Bionic Pancreas in Adults, Adolescents, and Pre-Adolescents
Moderator: R. Mack Harrell, MD
Speaker: Edward R. Damiano, MD

EDUCATIONAL OBJECTIVES:

  • Recognize the challenges that must be met to automate control of blood glucose levels in people with type 1 diabetes
  • List the elements of an automated closed-loop bionic pancreas
  • Describe the results of a recent clinical study of closed-loop blood glucose control using subcutaneous delivery of insulin and glucagon
9:00 am - 9:45 am TGS2: Neonatal Diabetes: Identification, Initial Treatment and Transitioning the Parent
Moderator: Yehuda Handelsman, MD
Speaker: Siri A. W. Greeley, MD EDUCATIONAL OBJECTIVES:
  • To become familiar with the most common monogenic etiologies of neonatal/congenital diabetes, with emphasis on mutations in the KATP channel that can be treated with sulfonylureas.
  • To appreciate the difference in treatment, disease outcome and quality of life that can result from properly diagnosing patients with monogenic diabetes. 
  • To understand the barriers to translating genetic findings into clinical treatment decisions and how these differ among babies compared older generations within the same family.
9:45 am - 11:00 am Exhibit Hall Coffee Break
10:00 am - 10:45 am Product Theaters in the Exhibit Hall
11:00 am - 11:45 am TGS3: Microarchitectural of Bone and its Clinical RElevance
Moderator: Pauline M. Camacho, MD
Speaker: John Paul Bilezikian, MD EDUCATIONAL OBJECTIVES:
  • To gain understanding of new imaging technologies that are clinically available
  • To gain insight into how new imaging technologies can add to what can be learned from DXA alone
  • To appreciate how certain metabolic bone diseases can be understood better by these new imaging technologies
11:45 am - 12:30 pm TGS4: The Link Between Retinopathy and vEGF: The Journey from Discovery Through Clinical Therapy
Moderator: Sandra L. Weber, MD
Speaker: Michael J.Tolentino, MD EDUCATIONAL OBJECTIVES:
  • Understand the molecular path that leads to diabetic retinopathy
  • Describe the history behind how current treatments for diabetic retinopathy were developed.
  • Define the role of VEGF in the development of diabetic retinopathy
12:30 pm - 2:15 pm President's Welcome Box Lunch in Exhibit Hall
12:45 pm - 1:30 pm Product Theaters in the Exhibit Hall
12:30 pm - 2:15 pm Women of Endocrinology Luncheon: If I Knew Then, What I Know Now (non – CME)
Moderator: Etie S. Moghissi, MD
Speaker: Camille Lee Senior Vice President, Dibaetes Marketing for NOvo Nordisk, Inc.
2:15 pm - 3:15 pm SESSION I
Meet-the-Experts
 

T11: Of Hispanics and Metabolism: Understanding the Risk of Diabetes
Moderator: Donald A. Bergman, MD
Speaker: Jaime A. Davidson, MD

EDUCATIONAL OBJECTIVES:

  • Based on the baseline findings of the Hispanic Community Health Study/Study of Latinos, examine the use of fasting plasma glucose, OGTT and HbA1c in the detection of pre-diabetes and diabetes mellitus in Hispanics/Latinos of diverse heritage groups
  • Review some biochemical and non-biochemical factors with potential interaction with these tests and relevant clinical implications to the diverse Hispanic/Latino population
  • Discuss opportunities for future research and interventions
 

T21: Testosterone Use: When and How;Testosterone Treatment in Young Males
Moderator: Elise M. Brett, MD
Speaker: Paul Turek, MD

EDUCATIONAL OBJECTIVES:

  • Describe the "saturation point" concept in testosterone replacement
  • Delineate 2 ways of improving testosterone balance and maintaining fertility potential
  • List 5 conditions besides hypogonadism that result in either low libido or erectile dysfunction
 

T31: Practicalities in the Use of Pharmacologic Agents
Moderator: Felice A. Caldarella, MD
Speaker: Caroline Apovian, MD

EDUCATIONAL OBJECTIVES:

  • Obesity is a disease and the evidence why
  • Understand the mechanism of action of the medications used to treat obesity
  • Identify two of the newer weight loss medications approved by the FDA for long-term use based on efficacy, safety, and tolerability
 

T41: Thyroid Ultrasound Images
Moderator: Mark A. Lupo, MD
Speaker: Robert A. Levine, MD

EDUCATIONAL OBJECTIVES:

  • Recognize commonly misinterpreted images in thyroid ultrasound.
  • Identify common anatomical variations that may be interpreted incorrectly on ultrasound
  • Recognize the role of scanning in multiple dimensions in ultrasound interpretation.
 

T51: Controversises in Osteoporosis Mangaement
Moderator: Daniel L. Hurley, MD
Speaker: Felicia Cosman, MD

EDUCATIONAL OBJECTIVES:

  • Review the Major Studies in whicch PTH tretament has been combined with antiresoprtive therapy.
  • Understand the differences between use of anabolic therapy in sequence with antiresorptive therapy-before and after.
  • How anabolic and antiresorptive therapy sequences can help achieve BMD targets in severe osteoporosis.
 

T61: (Point/Counterpoint) Subclincal Hypothyroidism: Treat or Not
Moderator: Timothy S. Bailey, MD
Speaker Point: Paul W. Ladenson, MD
Speaker Counter: Jeffrey R. Garber, MD

EDUCATIONAL OBJECTIVES (Point):

  • Determine cause of elevated serum TSH
  • Assess clinical significance of elevated serum TSH
  • Treat and monitor therapy of subclinical hypothyroidism
EDUCATIONAL OBJECTIVES (Counter):
  • The incidence of Subclinical Hypothyroidism
  • TSH normal range(s): impact of age, ethnicity, and stage of pregnancy
  • Subclinical Hypothyroidism: When to treat it and its impact on the development of cardiac disease
 

T71: (Case Review) Challenging Lipid Cases
Moderator: David S. H. Bell, MD
Speaker: Lisa Tannock, MD

EDUCATIONAL OBJECTIVES:

  • Understand use of lipid lowering medications beyond statins
  • Understand indications and potential risks of combination lipid therapies
  • Develop an approach to the medical management of lipids in high risk patients.
3:15 pm - 3:30 pm Coffee Break
3:30 pm - 4:30 pm SESSION II
Meet-the-Experts
 

T12: Emerging Therapies and Technologies for the Treatment of Diabetes
Moderator: S. Sethu K. Reddy, MD
Speaker: Irl B. HIrsch, MD

EDUCATIONAL OBJECTIVES:

  • Review the infrastructure required in an endocrine office to have downloading of all technology
  • Emerging therapy: Review GLP-1 and SGLT-2 inhibitors use and potential side effects in type 1 diabetes
  • Emerging technology: Describe past and future plans for development of the artificial pancreas
 

T22: Update on PCKS9 Inihibitors and New Therapies
Moderator: M. Kathleen Figaro, MD
Speaker: Evan A. Stein, MD

EDUCATIONAL OBJECTIVES:

  • Understand the role of PCSK9 in LDL metabolism
  • Understand the mechanism of PCSK9 inhibitors to reduce LDL-C
  • Be familiar with the efficacy and safety of PCSK9 monoclonal antibodies generated from phase 2 and 3 clinical trials
 

T32: Challenges in the Management of the Endocrine Patient: Transitions of Care from Pediatric to Adult Endocrinology
Moderator: Rajib Bhattacharya, MD
Speaker: A. Jay Cohen, MD

EDUCATIONAL OBJECTIVES:

  • Understand the specific challenges of endocrine disease states that endocrinologists deal with
  • Understand the patient challenges in transitioning from pediatric to adult endocrinologist
  • Understand the physician challenges in transitioning the patient from pediatric to adult endocrinologist
 

T42: The Nutritional Prevention and Reversal of Cardiovascular Disease- Fact or Fiction?
Moderator: Chris K. Guerin, MD
Speaker: Caldwell B. Esseltyn, MD

EDUCATIONAL OBJECTIVES:

  • Recognize endothelial injury as the inception of vascular disease.
  • Learn what nutrients can injure Endothelium
  • Understand how to prevent and reverse Cardiovascular Disease
 

T52: The Mind’s Role in Obesity
Moderator: Michael A. Bush, MD
Speaker: Joshua P. Thaler, MD

EDUCATIONAL OBJECTIVES:

  • Describe the basic brain systems governing energy homeostasis
  • Discuss pathologic processes implicated in the development of obesity
  • Apply an understanding of basic mechanisms underlying therapeutic approaches to improve clinical management of obesity
 

T62: Ectopic ACTH: Doagnosis and Treatments
Moderator: Janet B. McGill, MD
Speaker:Maria Fleseriu , MD

EDUCATIONAL OBJECTIVES:

  • Recognize the morbidity and mortality associated with hypercortisolemia
  • Review therapeutic options, including new options for ectopic Cushing's syndrome
  • Assess patient response to medical therapy for Cushing's syndrome
 

T72: (Case Review) Update on Pheochromocytoma and Paraganglioma: Implications for Clinical Practice
Moderator: Rachel Pessah-Pollack, MD
Speaker: Karel Pacak, MD

EDUCATIONAL OBJECTIVES:

  • Educate about newest genetic discoveries of Pheochromocytoma and paraganglioma
  • Educate about newest biochemical and imaging strategies to diagnose and localize Pheochromocytoma and parganglioma
  • Educate about current therapeutic approaches to Pheochromocytoma and paraganglioma
4:45 pm - 5:45 pm SESSION III
Meet-the-Experts
 

T13: Diabetes Transition from Pediatrics to Adulthood
Moderator: Dace L. Trence, MD
Speaker: Jennifer Raymond, MD

EDUCATIONAL OBJECTIVES:

  • Describe challenges and obstacles to successful transition to diabetes in adulthood
  • Identify different approaches to assisting with successful transition to diabetes in adulthood
  • Cite available resources and practice guidelines to facilitate with successful transition to diabetes in adulthood
 

T23: Statin Intolerance-Statin Side effects?
Moderator: Richard A. Haas, MD
Speaker: Lisa Tannock, MD

EDUCATIONAL OBJECTIVES:

  • Discuss adverse effects of statins (muscle symptoms, liver tests, diabetes)
  • Develop approaches to managing hyperlipidemia and cardiac risk in patients intolerant of statins
  • Discuss the risk/benefit ratio for statin use in cardiovascular disease prevention
 

T33: Later Effects in the Emerging Population of Childhood Cancer Survivors
Moderator: Vin Tangpricha, MD
Speaker: Sripriya Raman, MD

EDUCATIONAL OBJECTIVES:

  • Recognize the various endocrine late effects of childhood cancer therapy in adolescents and adults
  • Review the common causes of endocrine late effects from cancer therapy
  • Formulate individualized risk stratification and screening plan for childhood cancer survivors using national guidelines
 

T43: Update on Ectopic ACTH Rx, Especially with New Agents
Moderator: Janet B. McGill, MD
Speaker: Maria Fleseriu, MD

EDUCATIONAL OBJECTIVES:

  • Recognize the morbidity and mortality associated with hypercortisolemia
  • Review therapeutic options, including new options for ectopic Cushing's syndrome
  • Assess patient response to medical therapy for Cushing's syndrome
 

T53: Thyroid Ultrasound images
Moderator: Mark A. Lupo, MD
Speaker: Robert A. Levine, MD

EDUCATIONAL OBJECTIVES:

  • Recognize commonly misinterpreted images in thyroid ultrasound.
  • Identify common anatomical variations that may be interpreted incorrectly on ultrasound
  • Recognize the role of scanning in multiple dimensions in ultrasound interpretation.
 

T63: The Mind’s Role in Obesity
Moderator: Micahel A. Bush, MD
Speaker: Joshua P. Thaler, MD

EDUCATIONAL OBJECTIVES:

  • Describe the basic brain systems governing energy homeostasis
  • Discuss pathologic processes implicated in the development of obesity
  • Apply an understanding of basic mechanisms underlying therapeutic approaches to improve clinical management of obesity
  Case Review
 

T73: Challenging Thyroid Cases
Moderator: Robert Zimmerman, MD
Speaker: Paul W. Ladenson,
MD
Speaker: Susan J. Mandel, MD

EDUCATIONAL OBJECTIVES:

  • Evaluate unusual thyroid function tests
  • Manage complex thyroid cancer
6:00 pm - 7:00 pm Chapter & International Receptions
7:30 pm - 9:45 pm TSS3: Paradigm Shifts in Hypoparathyroidism: How New Insights in Epidemiology and Treatment are Changing the Standard of Care
6:45 pm - 7:45 pm Dinner
7:45pm - 9:00pm TSS4: Combintaion Therapy in Type 2 Diabetes Management: Charting Courses for Success
FRIDAY, MAY 16
5:15 am - 5:45 am Breakfast
5:15 am - 7:30 am FSS1: Prevention and Management of Diabetic Retinopathy and Related Eye Disorders: Clarifying the Endocrinologist’s Role
5:15 am - 7:30 am FSS2: Applying the Fundamentals of Insulin Physiology to Modernize Exogenous Insulin Therapy: An Expert Panel Exhange and Interactive Town Hall Discussion
7:30 am - 6:30 pm Attendee Registration
7:30 am - 6:30 pm CME Station Hours
9:45 am - 2:15 pm Exhibit Hall Hours
8:00 am - 8:15am General Session Announcements / Poster Awards
8:15 am - 9:00 am

FGS1: Molecular Drivers for Fat Genesis and their Roles in Diabetes and Obesity
Moderator: Daniel Einhorn, MD
Speaker: Ronald M. Evans, MD

EDUCATIONAL OBJECTIVES:

  • Though body-wide phenomena, does insulin resistance emerge from a single origin?
  • What is the definition of an insulin sensitizing drug?
  • Can biology be developed that promote insulin sensitization?
9:00 am - 9:45 am

FGS2: Short-term and Long-term Impacts of Genetic Discovery on the Practice of Endocrinology
Moderator: Robert Rapaport, MD
Speaker: Joel Hirschhorn, PhD

EDUCATIONAL OBJECTIVES:

  • Understand the route from genetic discovery to biological insight to new therapies
  • Assess the potential impact of different types of genetic information on individual clinical management
  • Recognize different types of genetic methods for research and clinical practice
9:45 am - 11:00 am Exhibit Hall Coffee Break
10:00 am - 10:45 am Product Theaters in the Exhibit Hall
11:00 am - 11:45 am MINI Plenary Sessions
  FGS3: Transcultural Endocrinology Symposium
Chair: Jeffrey I. Mechanick, MD
  • Diabetes in India
    Shashank R. Joshi, MD
  • Diabetes in the Persian Gulf
    Osama Hamdy, MD
  • Diabetes in Nigeria and Sub-Saharan Africa
    Samuel Dagogo-Jack, MD
  • Diabetes in Costa Rica
    Jaime A. Davidson, MD
  • The Pan-American AACE Trancultural Workshop
    Jeffrey I. Mechanick, MD
EDUCATIONAL OBJECTIVES:
  • Review the main structure of the Diabetes Nutrition Algorithm
  • Outline the major nutrition problems in relation to obesity and diabetes in the Middle East
  • Recognize the adaptation of the Algorithm for the Middle East and review the toolkit for PCPs and endocrinologists
EDUCATIONAL OBJECTIVES:
  • How Costa Rica a small country with 52,000 square kilometers compares in the treatment of type 2 diabetes with larger and more developed countries‎.
  • The changes in the prevalence of diabetes in the last 2 decades
  • How Costa Rica‎ health care system recommends pharmacological interventions in Diabetes 
  • Costa Rica has universal health. Does it make a difference in outcomes
  FGS4: Oral Presentations – CME
Co-Moderators: Edward S. Horton, MD and David C. Lieb, MD (Abstract Review Subcommittee Co-Chairs)
 
  • Neck Circumference - A More Inofrmative Indictaor For Metabolic Disturbances Compared To Waist Circumference?
    Zdravko Kamenov, MD, PhD, DMsc
  • Bariatric Surgery Restores Somatic And Autonomic Nerve Function Towards Normal In Obese Patients With And Without Diabetes
    Aaron Vinik, MD, PhD, FCP, FACP, FACE
  • Pamidronate For Bone Hyperresorption In Chronic Critical Illness Is Associated With Improved Outcomes And Renal Parameters
    Rifka Schulman, MD
EDUCATIONAL OBJECTIVES:
  • Evaluate the role of neck circumference measurement in comparison to waist circumference as indicators for metabolic disturbances.
  • Interpret different anthropometric indicators.
  • Recognize the importance of neck circumference measurement for the everyday clinical practice. 
EDUCATIONAL OBJECTIVES:
  • Illustrate the clinical presentation of a patient with neuropaoth7y involving the somatic and autonomic nervous systems
  • Provide an algorithm for bedside testing to elicit the diagnosis as well as any more sophisticated testing
  • Discuss the clinical approach to managing the different component s of the disorder
EDUCATIONAL OBJECTIVES:
  • Understand the pathophysiology of chronic critical illness (CCI) related bone hyperresorption.
  • Appreciate the associations between pamidronate use and mortality, ventilator liberation, nutritional markers, glucose control, and renal parameters in a CCI cohort.
  • Reflect on potential physiological mechanisms involved in the relationship between pamidronate use and outcomes in a CCI cohort.
 

FGS5:Thyroid: The Year in Review
Moderator: Peter A. Singer, MD
Speaker: Susan J. Mandel, MD

EDUCATIONAL OBJECTIVES:

  • Review the salient research findings in thyroidology
  • Understand implications of these findings for clinical practice
  • Appraise the advancement of the field based upon most recent publications
11:45 am - 12:30 pm MINI Plenary Sessions
  FGS6: Late Breaking/Clinical Trials – Non - CME
Moderators: Alan J. Garber, MD; Janet B. McGill, MD
  FGS7: Oral Presentations – Non CME
Co-Moderators: Edward S. Horton, MD and David C. Lieb, MD (Abstract Review Subcommittee Co-Chairs)
  • Reduction In Brain Tissue Perfusion With High Blood Sugar
    Paresh Dandona, MD, PhD, FACE
  • Timing Of Postoperative Radioactive Iodine Ablation Does Not Impact Overall Survival In High Risk And Metastatic Papillary Thyroid Carcinoma
    Paritosh Suman, MD
  • Eight Year Follow-Up Of 378 Consecutive Low-Intermediate Risk Differentiated Thyroid Cancer Patients Without I131 Ablation In A Community Based Setting.
    Kathleen Hands, MD, FACE, ECNU
EDUCATIONAL OBJECTIVES:
  • Better understand and formulate the timing of postoperative radioactive iodine ablation.
  • Use the data in discussions with their papillary thyroid carcinoma patients about the usefulness of delayed radioactive iodine ablation.
  • Recognize the factors which impact and does not impact overall survival in high risk and metastatic papillary thyroid carcinoma patients.
EDUCATIONAL OBJECTIVES:
  • Understand roots of RAI use
  • Understand limitations of RAI in low risk DTC
  • Feel confident avoiding use RAI in low risk DTC
12:30 pm - 2:15 pm Exhibit Hall Break
12:45 pm - 1:30 pm Product Theaters in the Exhibit Hall
2:15 pm - 5:00 pm In-Depth Symposia
  F11: Transition from Childhood to Adulthood
Chair: Robert Rapaport, MD
  • Transition of Young Adults with Diabetes Mellitus
    William Tamborlane, MD
  • PCOS in the adolescent and Young Adult-Diagnosis, Treatment, and Implications
    Phyllis Speiser, MD
  • Transitioning Survivors of Childhood Cancer to Adult Endocrine Providers
    Charles Sklar, PhD
  • Growth Hormone Transition
    Ron Rosenfeld, MD
EDUCATIONAL OBJECTIVES:
  • Describe current A1c levels as patients with T1D transition from adolescence to young adulthood
  • Cite the incidence of severe hypoglycemia and DKA as patients with T1D transition from adolescence to young adulthood
  • Cite the use of advanced diabetes technologies as patients with T1D transition from adolescence to young adulthood.
EDUCATIONAL OBJECTIVES:
  • Describe standard diagnostic criteria for PCOS
  • Summarize unique aspects of pituitary-ovarian function in adolescents
  • Differentiate PCOS from other diagnostic entities
EDUCATIONAL OBJECTIVES:
  • Review risk factors for late endocrine complications in adult survivors of childhood cancer
  • Identify those survivors requiring periodic endocrine screening as they age
  • Recommend screening guidelines for survivors at risk of developing endocrine complications as they age
EDUCATIONAL OBJECTIVES:
  • Understanding of the potential benefits of growth hormone in adult life
  • Understanding diagnostic procedures required during transition to adult life
  • Understanding GH dosing during transition and in adult life
  F21: Advances in Thyroid Cancer
Chair: Hossein Gharib, MD
  • Medullary Thyroid Cancer Imaging
    Jolanta Durski, MD
  • Thyroid and Nodal Surgery for Thyroid Cancer
    Gregory Randolph, MD
  • Radioiodine Therapy: Why, When and How Much?
    Douglas Van Nosrand, MD
  • Recurrent Thyroid Cancer: What to do & When?
    R. Michael Tuttle, MD
EDUCATIONAL OBJECTIVES:
  • Know the indications for whole body radioiodine scans, patient preparation and technique
  • Know the indications for FDG-PET scan in thyroid patients, patient preparation and technique
  • Be familiar with a few investigational PET tracers
EDUCATIONAL OBJECTIVES:
  • To be aware of the effect of thyroid surgery on voice
  • To improve awareness of the importance of preop nodal mapping
  • To review the anatomy of the nerves that regulate voice production
EDUCATIONAL OBJECTIVES:
  • Define the three categories of radioiodine therapy.
  • List the spectrum of indications for I-131 remnant ablation, adjuvant treatment and treatment of known locoregional and/or distant metastases.
  • Discuss the spectrum of prescribed activity for I-131 remnant ablation, adjuvant treatment and treatment of known locoregionaland/or distant metastases.
EDUCATIONAL OBJECTIVES:
  • To review risk stratification in thyroid cancer
  • To explore how risk stratification impacts initial management
  • To define how ongoing risk stratification guides long term follow-up
  F31: Primary Hyperparathyroidism: New Insights and Guidelines for Management
Chair: Pauline M. Camacho, MD
  • Beyond DXA: Application of New Imaging technologies to Metabolic Bone Diseases
    John Bilezikian, MD
  • Secondary Prevention of Fractures: Fraction Liasion Programs
    Robert R. Recker, MD
  • Role of Bone Turnover Markers in the Management of Osteoporosis
    Nelson Watts, MD
  • Bone as an Endocrine Organ
    Clifford J. Rosen, MD
EDUCATIONAL OBJECTIVES:
  • To gain understanding of new imaging technologies that are clinically available
  • To gain insight into how new imaging technologies can add to what can be learned from DXA alone
  • To appreciate how certain metabolic bone diseases can be understood better by these new imaging technologies
EDUCATIONAL OBJECTIVES:
  • Describe the risk of subsequent fracture after the first osteoporotic fracture
  • Describe the defects in health care systems that inhibit ideal post-hospital care of osteoporosis fracture cases
  • Describe effective programs that remove the factors that inhibit post-hospital care of osteoporosis fracture cases
EDUCATIONAL OBJECTIVES:
  • Become familiar with different markers of bone turnover
  • Understand what BTMs tell us about the mechanism of action of pharmacologic agents
  • Describe the clinical questions that bone turnover markers might answer.
EDUCATIONAL OBJECTIVES:
  • Understand the physiology of bone as a secretory organ
  • Define the hormonal factors that influence whole body metabolism from bone
  • Examine potential therapeutic targets for the skeleton
  F41: Assessing the Benefits and Risks of Testerone Therapy in Men and Women
Co-Chairs: Paresh Dandona, MD & Neil Goodman, MD
  • Introduction of AACE Guidelines
    Paresh Dandona, MD & Neil Goodman, MD
  • Low T Syndrome: What Men should receive Testosterone and How Much?
    Sandeep Dhindsa, MD
  • CV Risks & Benefits of Testosterone Therapy
    Paresh Dandona, MD
  • Testosterone Replacement Therapy for Women? Who, When and How Much?
    Susan Davis, MD
EDUCATIONAL OBJECTIVES:
  • Consequences of low testosterone
  • Appropriate candidates for testosterone replacement therapy
  • Monitoring testosterone replacement therapy
EDUCATIONAL OBJECTIVES:
  • Assessment of CV risks in conditions associated with Hypogonadism
  • Actions of testosterone in relation to Diabetes and Obesity
  • CV outcome trials related to testosterone therapy
EDUCATIONAL OBJECTIVES:
  • Understand the basic physiology of testosterone
  • Understand reasons for low testosterone in women
  • Understand when and how to treat women with testosterone
  F51: Novel Therapeutic Approaches to Type 2 Diabetes and Complications
Chair: Robert Henry, MD
  • Current Clinical Status of Incretin Hormones
    David D’Alessio, MD
  • The Kidney, Intestine or Both as Therapeutic Targets in Diabetes
    James D. Gavin III, MD
  • New Insulin and Insulin GLP-1 Combinations in Development: Application and Therapeutic Efficacy
    John B. Buse, MD
  • Update on Peripheral Neuropathies: Diagnosis and Therapies
    Arthur I. Vinik, MD
EDUCATIONAL OBJECTIVES:
  • List the key target organs for GLP-1 and GIP
  • Compare and contrast the actions of GLP-1 receptor agonists and DPP-4 inhibitors to reduce blood glucose in diabetic patients.
  • Describe the major side effects of GLP-1 receptor agonists
EDUCATIONAL OBJECTIVES:
  • Assess the physiologic complexity and heterogeneity of diabetes mellitus
  • Determine the roles of the gut and kidney as non-beta cell dependent targets in diabetes therapy
  • Design treatment approaches that safely and effectively utilize the gut and/or kidney as treatment targets in DM
EDUCATIONAL OBJECTIVES:
  • Identify novel injectable in phase 3 trials and under regulatory review
  • Understand the available safety and efficacy data from the available studies
  • Recognize the incomplete nature of the available data and the need to robustly apply current technologies
EDUCATIONAL OBJECTIVES:
  • Illustrate the heterogeneity of neuropathies in diabetes
  • Provide clear and straightforward guidelines for diagnosis of the different forms of neuropathy
  • Provide an algorithm for management of neuropathic pain based upon the comorbidities including sleep disturbance, anxiety and depression
  F61: Lipid Guidelines: Can We Identify the Risk, but Not the Numbers?
Chair: Kittie Wyne, DPM
  • Harmonizing the Lipid Guidelines: AACE, NLACC, ADA, IAS, and Beyond
    Scott Grundy, MD
  • Advanced Lipid Testing: LDL particles for the Clinician
    Peter Jones, MD
  • Triglyceride Lowering Agents: Should they be used Outside a Lipid Clinic?
    Eliot Brinton, MD
  • New Treatments for Hypercholesterolemia: Apheresism,Mipomersen, Lomitapide, & PCKS9 Inhibitors
    James Falko, MD
EDUCATIONAL OBJECTIVES:
  • What does the evidence state?
  • In secondary prevention, the lower the better?
  • In primary prevention, the lower the better?
EDUCATIONAL OBJECTIVES:
  • Discuss the various methods available to assess risk for atherosclerotic cardiovascular disease
  • Describe the value of lipid targets for the prevention of cardiovascular disease
  • Compare the alternative methods of lipid measurements as targets of therapy
EDUCATIONAL OBJECTIVES:
  • Define Familial Hypercholesterolemia (FH)
  • Describe the prevalence and the associated CV Risk
  • Evaluate and discuss the new treatments in Apheresism,Mipomersen, Lomitapide, & PCKS9 Inhibitors
  F71: AACE/SMNE Pan American Symposia: Lifestyle, Metabolic Disorders and Cancer
Co-Chairs:Myriam Allende-Vigo, MD
  • Regulation of Appetite and Food In-Take-Role of Peripheral and Central Mediators
    Myriam Allende-Vigo, MD
  • Diabetes Prevention- Type 1 and 2 diabetes-Pediatric
    Elisabeth Solis, PhD
  • New Drugs for Obesity Mangement: Pharmacology, Appropriate Uses and Outcomes
    J. Michael Gonzalez-Campoy, MD
  • Relationship of Diabetes, Obesity ad Cancer
    Francisco Pasquel, MD
EDUCATIONAL OBJECTIVES:
  • Assess the complex interplay between neuropeptides and hormones in the control of appetite and food intake.
  • Be able to enumerate mediators of appetite and food intake that act at the central nervous system.
  • Be able to name mediators of food intake that are secreted in peripheral tissues and organs.
EDUCATIONAL OBJECTIVES:
  • To identify the strategies for Diabetes prevention during childhood in Nuevo León, México
  • To distinguish the importance of the role of Nutrition in Health Promotion and chronic disease prevention
  • To detect Diabetes prevention services in Clinical and Community settings
EDUCATIONAL OBJECTIVES:
  • Outline the principles of medical practice in bariatric endocrinology.
  • Review AACE recommended for the treatment of obesity.
  • Discuss therapeutic options, focusing on pharmacotherapy for obesity.
EDUCATIONAL OBJECTIVES:
  • Describe the epidemiological association between obesity, diabetes and cancer
  • Identify potential mechanisms linking obesity, diabetes and cancer
  • Identify factors associated with increased risk of cancer in subjects with obesity and diabetes
5:00 pm - 6:45 pm Exhibit Hall Wine & Cheese Reception
7:00 pm - 9:15 pm FSS3: Continuous Covergae and Clinical Application of Real Time CGM:Pathway to Improved Outcomes and Reduced Cost
7:00 pm - 9:15 pm FSS4: managing Obesity in 2015: Setting the Framework and Assessing All of the Options
7:00 pm - 7:30 pm Dinner
SATURDAY, MAY 17
7:30 am - 5:00 pm Attendee Registration
7:30 am - 6:00 pm CME Station Hours
9:45 am - 1:00 pm Exhibit Hall Hours
8:00 am - 8:15 am General Session Announcements
8:15 am - 9:00 am

SGS1: The Three Pathways of Translational Research: Diabetes and a Personal Experience
Moderator: Jeffrey I. Mechanick, MD
Speaker: Valentin Fuster, MD

EDUCATIONAL OBJECTIVES:

  • The present trend in the cardiovascular field is a "movement" from treating disease (which will always be the case) to promoting health. 
  •    Over the last 30 years the translational approach from the “laboratory to the patient” has shifted to the approach from “global observations and guidelines to the patient and from the patient to the laboratory.”
  • The presentation will entail a parallel of the above trends in the cardiovascular field and diabetes and the presenter’s investigational approach to such trends, since he was a medical student.
  • The presentation is dedicated to the young investigators and fellows with a focus on their future.
9:00 am - 9:45 am

SGS2: Deletions and Mutations in the Growth Hormone- Receptor ( Laron Syndrome): Genetic, Biological and Clinical Aspects
Moderator: Jaime A. Davidson, MD
Speaker: Zvi Laron, MD

EDUCATIONAL OBJECTIVES:

  • Diagnosis and treatment of Laron Syndrome
  • Differential diagnosis of short stature
  • Description of postnatal effects of congenital IGF-I deficiency in combination with lack of growth hormone activity Pharmacology and clinical effects of IGF-I treatment
9:45 am - 11:00 am Exhibit Hall Coffee Break
10:00 am - 10:45 am Product Theaters in the Exhibit Hall
11:00 am - 11:45 am

SGS3: Metformin: Its Non-Glycemic Effects and Cardiovascular Risk Reduction
Moderator: Anne L. Leddy, MD
Speaker: John M. Miles, MD

EDUCATIONAL OBJECTIVES:

  • Discuss the role of metformin in reducing the risk of cardiovascular events
  • Understand the pharmacokinetics and pharmacodynamics of metformin
  • Discuss the safety of metformin in patients with heart failure and chronic kidney disease
11:45 am - 12:30 pm

SGS4: Disordered Growth Hormone Secretion in HIV: Mechanisms and Novel Therapeutic Strategies
Moderator: Felice A. Caldarella, MD
Speaker: Steven K. Grinspoon, MD

EDUCATIONAL OBJECTIVES:

  • To understand altered GH secretion in HIV lipodystrophy as a model for disordered GH secretion in obesity
  • To understand the range of options to address altered GH secretion in HIV lipodystrophy
  • To learn of the therapeutic potential of a GHRH analogue to reduce abdominal fat and triglyceride in HIV patient
12:30 pm - 2:15 pm AACE Annual Business Meeting Luncheon
2:15 pm - 3:15 pm SESSION I
Meet-the-Experts
 

S11: Year in Diabetes
Moderator: Etie S.Moghissi, MD
Speaker: Claresa Levetan, MD

EDUCATIONAL OBJECTIVES:

  • To provide the past, present and future of diabetes treatment
  • To distinguish between islets and beta cells
  • To demonstrate the role of the 5 other hormones made within the islet and their role with insulin for glucose homeostasis
 

S21: FGF: New Guy On Scene
Moderator: Sunil Wimalawansa, MD
Speaker: Brian Kestenbuam, MD

EDUCATIONAL OBJECTIVES:

  • Understand the discovery of FGF-23
  • Understand the role of FGF-23 in phosphate and vitamin D metabolism
  • Understand the role of FGF-23 in kidney disease
 

S31: Neurohumoral Syndromes
Moderator: Derek Leroith, MD
Speakers: Arthur I. Vinik, MD

EDUCATIONAL OBJECTIVES:

  • Illustrate the clinical presentation of a patient with neuropathy involving the somatic and autonomic nervous systems
  • Provide an algorithm for bedside testing to elicit the diagnosis as well as any more sophisticated testing
  • Discuss the clinical approach to managing the different component s of the disorder
 

S41: Hyperandrogenic Anovulation
Moderator: W. Reid Litchfield, MD
Speaker: Margaret Wierman, MD

EDUCATIONAL OBJECTIVES:

  • Outline the differential causes of elevated androgens in pre and postmenopausal women
  • Discuss the best laboratory evaluation for clinical signs of hyperandrogenism
  • Understand the treatment options available for treatment of hyperandrogenism
 

S51: The Year in Pituitary Disease
Moderator: Ved Gossain, MD
Speakers: Mark Molitch, MD

EDUCATIONAL OBJECTIVES:

  • Discuss new medical treatments for pituitary diseases
  • Discuss new diagnostic modalities for pituitary diseases
  • Discuss current concepts regarding the pathophysiology of pituitary diseases
  Point/Counterpoint
 

S61: To Use or Not: Molecular Markers
Moderator: Jonathan Leffert, MD
Speaker Point: Bryan McIver, MD
Speaker Counter:Mark A. Lupo, MD

EDUCATIONAL OBJECTIVES:

  • Include commercially available molecular marker panels to evaluation of thyroid nodules in clinical practice
  • Understand the impact of pre-test risk of malignancy on the performance of these assays
  • Recognize the limitations of molecular markers and the importance of incorporating clinical, ultrasound and cytological features into the decision making process
EDUCATIONAL OBJECTIVES:
  • Explore the utility of FNA-derived markers in the surgical decision making for patients with thyroid nodules.
  • Examine current published data on the accuracy of "negative/benign" molecular markers in nodules with Bethesda III and Bethesda IV cytology.  Is it safe to observe these patients without surgery?
  • Differentiate clinical scenarios requiring a test with high NPV from those requiring a test with high PPV.
  • Discuss the clinical and sonographic features that may influence the decision whether or not to use molecular markers.
  Case Review
 

S71: Thyroid Cases: Weird and the Not so Unusual
Moderator: Farhad Zangeneh, MD
Speaker: Jeffrey R. Garber, MD

EDUCATIONAL OBJECTIVES:

  • Know the differential diagnosis of T3 Toxicosis
  • Know how long it takes for a suppressed Hypothalamic Pituitary Axis to Recover
  • Know the pathophysiologic mechanism of Pemberton's Sign
3:15 pm - 3:30 pm Coffee Break
3:30 pm - 4:30 pm SESSION II
Meet-the-Experts
 

S12: Update on the Impact of Sleep Disturbances in Metabolic Disorders
Moderator: Joseph A. Aloi, MD
Speaker: Eve Van Cauter, MD

EDUCATIONAL OBJECTIVES:

  • Understand the role of insufficient sleep in the risk of obesity and diabetes
  • Understand the role of poor sleep quality in the risk and severity of type 2 diabetes
  • Understand the role of circadian misalignment in the risk and severity of type 2 diabetes
 

S22: ICD-10
Moderator: Katherine Roberts, MD
Speaker: Todd W. Frieze, MD

EDUCATIONAL OBJECTIVES:

  • Explain the differences between ICD-9-CM and ICD-10-CM
  • Review the benefits of ICD-10-CM
  • Understand the implications and challenges endocrinology clinics face with ICD-10-CM
 

S32: Lipidystrophy
Moderator: Felice A. Caldrealla, MD
Speakers: Savitha Subramanian, MD

EDUCATIONAL OBJECTIVES:

  • Understand the classification of lipodystrophic syndromes
  • Recognize clinical features of lipodystrophy
  • Treat clinical manifestations of lipodystrophy
 

S42: PCOS in Adolescent Girls: Diagnosis and Management
Moderator: Sripriya Raman, MD
Speaker: Selma Witchel, MD

EDUCATIONAL OBJECTIVES:

  • To review diagnostic criteria for PCOS in adolescents
  • To review goals of treatment for adolescent girls
  • To recognize barriers to transition of care for
 

S52: Treatment of Progressive Thyroid Cancer
Moderator: Gregory Randolph, MD
Speaker: Steven I. Sherman, MD

EDUCATIONAL OBJECTIVES:

  • To recognize appropriate clinical criteria for selection of patients suitable for systemic therapy of progressive thyroid cancer
  • To identify the mechanisms underlying systemic therapy options
  • To select among treatment options for systemic therapy of patients with progressive thyroid cancer
 

S62: Neurohumoral Syndromes
Moderator: Derek Leroith, MD
Speakers: Arthur I. Vinik, MD

EDUCATIONAL OBJECTIVES:

  • Illustrate the clinical presentation of a patient with neuropathy involving the somatic and autonomic nervous systems
  • Provide an algorithm for bedside testing to elicit the diagnosis as well as any more sophisticated testing
  • Discuss the clinical approach to managing the different component s of the disorder
 

S72: Preventing Type 2 Diabetes in Latino Youth: Transltaional Science to Clinical Relevance
Moderator: Craig Wierum, MD
Speakers: Gabriel Shaibi, MD

EDUCATIONAL OBJECTIVES:

  • Identify novel risk factors for type 2 diabetes in youth
  • Define critical differences in type 2 diabetes between children and adults
  • Outline key aspects of type 2 diabetes prevention programs for youth
4:45 pm - 5:45 pm SESSION III
Meet-the-Experts
 

S13: Normocalcemic Hyperparathyroidism
Moderator: Gary Edelson, MD
Speaker: Shonni Silverberg,, MD

EDUCATIONAL OBJECTIVES:

  • Understand presentation and manifestations of primary hyperparathyroidism as it presents today
  • Identify which patients should be sent for parathyroidectomy under 2014 International Guidelines
  • Understand role of medical intervention in primary hyperparathyroidism under 2014 International Guidelines
 

S23: Endocrine Jeopardy
Moderator: Ricardo Correa, MD
Speaker: Cheryl R> Rosenfeld, MD

EDUCATIONAL OBJECTIVES:

  • Identify signs and symptoms of endocrine disorders
  • Recognize ultrasound variants of thyroid nodules and cancer
  • Recall important events in endocrine history
 

S33: Update on the Impact of Sleep Disturbances in Metabolic Disorders
Moderator: Joseph A. Aloi, MD
Speaker: Eve Van Cauter, MD

EDUCATIONAL OBJECTIVES:

  • Understand the role of insufficient sleep in the risk of obesity and diabetes
  • Understand the role of poor sleep quality in the risk and severity of type 2 diabetes
  • Understand the role of circadian misalignment in the risk and severity of type 2 diabetes
 

S43: Subclinical Cuhsing’s
Moderator: Donald W. Richardson, MD
Speaker: John D. Carmicheal, MD

EDUCATIONAL OBJECTIVES:

  • Identify diagnostic criteria and the clinical context for the diagnosis of Sub-Clinical Cushing's Syndrome
  • Describe the clinical signs and symptoms associated with Cushing's Syndrome and their associated sensitivities and specificities in making a diagnosis
  • Differentiate between clinical situations that comprise false positive testing or true Cushing's Syndrome
 

S53: Neutroceuticals
Moderator: Shashank R. Joshi, MD
Speaker: Kenneth D. Burman, MD

EDUCATIONAL OBJECTIVES:

  • Understand the regulatory definitions of Neutroceuticals and dietary supplements
  • Know the specific types of commonly used Neutroceuticals and dietary supplements
  • Know the specific types of commonly used Neutroceuticals and dietary supplements
 

S63: Treatment of Progressive Thyroid Cancer
Moderator: Gregory Randolph, MD
Speaker: Steven I. Sherman, MD

EDUCATIONAL OBJECTIVES:

  • To recognize appropriate clinical criteria for selection of patients suitable for systemic therapy of progressive thyroid cancer
  • To identify the mechanisms underlying systemic therapy options
  • To select among treatment options for systemic therapy of patients with progressive thyroid cancer
  Point/Counterpoint
  EDUCATIONAL OBJECTIVES:
  • Describe race-specific associations of HbA1c with long-term complications
  • Understand the clinical implications of racial differences in HbA1c
  • Critically evaluate the controversy regarding racial differences in HbA1c
EDUCATIONAL OBJECTIVES:
  • Appreciate the limitations of self-reported data on disease prevalence
  • Compare ethnic patterns of self-reported diabetes data with the pattern observed from actual glucose measurement
  • Identify potential explanations for dissociation between prevalence and incidence data regarding diabetes
6:30 pm ACE Convocation
7:30 pm President's Gala
SUNDAY, MAY 18
7:00 am - 11:30 am Attendee Registration
7:30 am - 12:15 pm CME Station Hours
7:00 am - 8:00 am Breakfast
8:00 am - 8:15 am General Session Announcements
8:00am - 11:00am Oral Presentationa on Planning Research in Diabetes (PRIDE)
(non-CME)
8:15 am - 9:00 am

SGS5: AACE/AAES Joint Review of Cases on Hyperparathyroidism
Moderator: Nancy D. Perrier, MD
Speakers: Mira Miles, MD & Shonni J. Silverberg, MD
Case Title: The Phantom "Parathyroid"
Case Presenter: Eric J. Finnesgard, BA

EDUCATIONAL OBJECTIVES:

  • Consider uncommon etiologies for hypercalcemia.
  • Reflect upon the complexity of calcium metabolism.
  • Translate experiential lessons from this case to their own practice.

Case Title: A Failed Parathyroid Exploration... Or is It?
Case Presenter: Janice L Pasieka MD

EDUCATIONAL OBJECTIVES:

  • Review the difficulty with the biochemical diagnosis of HPT in Vitamin D deficiency
  • Intra operative challenges when iPTH fails to fall
  • Role for genetic testing in 'failed' parathyroid surgery

Case Title: A Parathyroid Lost, Then Found…Then Lost Again?
Case Presenter: Latha V. Pasupuleti, MD

EDUCATIONAL OBJECTIVES:

  • To Recognize and Evaluate Persistent hyperparathyroidism and identify the surgical strategies that should be employed to locate ectopic parathyroid glands during a bilateral neck exploration.
  • To diagnose a rare cause of resolution of persistent hyperparathyroidism and understand the follow up and management of this condition.
  • To describe the comprehensive diagnostic work up that should be used to localize ectopic hyperparathyroid glands that could not be found during surgical exploration in patients with persistent hyperparathyroidism.

Case Title: Interesting Case of an Ectopic Parathyroid Adenoma
Case Presenter: Jason P. Calligas, MD

EDUCATIONAL OBJECTIVES:

  • Understand the migration of the parathyroid glands
  • Describe the typical management of parathyroid adenomas
  • Describe uncommon locations of parathyroid adenomas
9:15 am - 10:00 am

SGS6: AACE/AAES Joint Review of Cases on Thyroid Cancer Management
Moderator: Carmen C. Solorzano, MD
Speakers: Gregory Randolph, MD & R. Michael Tuttle, MD

Case Title: “A Stressful Cough; A Pain In The Back.”
Case Presenter: Vikram D Krishnamurthy, MD

LEARNING OBJECTIVES:

  • Identify the clinical presentation of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia
  • Identify the pathologic findings of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia
  • Describe the work-up of hypercortisolism

Case Title: Case of the Misleading Neck Mass
Case Presenter: Shelby Holt, MD

EDUCATIONAL OBJECTIVES:

  • Be able to list the differential diagnosis of paratracheal mass
  • Recognize cytopathologic of the various etiologies of paratracheal masses.
  • Recognize the pitfalls in diagnostics evaluation of paratracheal masses

Case Title: Chain of Endocrine Events
Case Presenter: Alexander Shifrin,MD

EDUCATONAL OBJECTIVES:

  • To learn unusual presentation of endocrine malignancy
  • To understand physiology and relationship between different organs of endocrine origin
  • To learn management of complex endocrine condition

Case Title: A Men-1 Patient With Upper Gastrointestinal Bleeding: What Is The Cause And Where Is The Primary Tumor?
Case Presenter: Eden C. Payabyab, MD

EDUCATIONAL OBJECTIVES:

  • Identify the Most common cause of upper gastrointestinal bleeding in MEN1 patients
  • Describe the work up and management of UGI Bleeding n MEN 1 patients
  • Describe the management pf metastatic neuroendocrine tumor in a MEN 1 patient
10:15 am - 11:00 am

SGS7: AACE/AAES Joint Review of Cases on adrenal Nodules
Moderator: Gerard Doherty, MD
Speakers: Clive S. Grant, MD & Gary Hammer, MD
Case Title: A Nerve-ous Predicament
Case Presenter: Jessica Folek, MD

EDUCATIONAL OBJECTIVES:

  • Illustrate a case involving the decision of whether to stage removal of a contralateral lobe in total thyroidectomy for papillary thyroid cancer, following evidence of neuropraxia injury of the recurrent laryngeal nerve, as demonstrated by intraoperative nerve monitoring.
  • Describe how to recognize neuropraxia injury with a visually intact recurrent laryngeal nerve and its clinical significance.
  • Illustrate a case of vagal nerve schwannoma, and describe options for management. Discuss differential diagnoses of masses arising in the carotid space.

Case Title: Rare Adrenal Malignancy In A Patient With Acquired Immune Deficiency Syndrome And Epstien-Barr Virus
Case Presenter: Aida Taye, MD

LEARNING OBJECTIVES:

  • Learn about the management of adrenal mass in a patient with AIDS and EBV.
  • Discuss the rare presentation of the disease.
  • Learn about adrenaleiomyosarcoma.

Case Title: Total Eclipse of the Heart
Case Presenter: Courtney Lee, MD

LEARNING OBJECTIVES:

  • Review presentation and diagnosis of adrenergic crisis
  • Describe options for preoperative blockade in an acute setting
  • Illustrate a multidisciplinary approach to a complex endocrine problem

Case Title: MEN what? A Tour of the Endocrine Glands
Case Presenter: Priya Dedhia, MD, PhD,

LEARNING OBJECTIVES:

  • Examine the cytologic meaning of high grade malignant neoplasm.
  • Identify causes simultaneously affecting multiple endocrine organs
  • Review the specifics of diffuse intravascular B-cell lymphoma
11:00 am - 11:15 am Final Announcements; Adjournment